Core Insights - Jim Cramer provided insights on ImmunityBio, Inc. (NYSE: IBRX), suggesting it is a speculative investment due to the company's significant financial losses [1][3] - Cramer expressed uncertainty about the stock's recent trading activity, indicating a need for caution before making any purchases [3] Company Overview - ImmunityBio, Inc. focuses on developing therapies aimed at enhancing the immune system to combat infectious diseases and various cancers [3] Investment Perspective - While ImmunityBio has potential, there are other AI stocks that may offer better upside potential with lower downside risk [4]